Voyager Therapeutics selects lead development candidate for SOD1 ALS gene therapy programme
ALS is a progressive neurodegenerative disease which sees motor neurons atrophy and die, leading to loss of the ability to speak, move, eat and, ultimately even breathe. Voyager